Coalition for the Reversal of Breast Cancer Mortality in African American Women

A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond

Showing posts with label fda. Show all posts
Showing posts with label fda. Show all posts
Friday, November 1, 2013

PONATINIB: ARIAD ASKED TO STOP PRODUCTION !

›
THROMBOTIC EVENTS AND POSSIBLE VASCULOPATHY MAY HAVE LED TO THE FDA ORDER TO SUSPEND REPORTEDLY THE PRODUCTION OF PONATINIB A DRUG JUST RECE...
Monday, February 25, 2013

›
NEWS FROM THE FDA! 1.PEGINESATIDE A DRUG INDICATED FOR ANEMIA OF CHRONIC RENAL FAILURE HAS BEEN PULLED FROM THE MARKET BECAUSE OF 3 DEATHS...
Wednesday, February 13, 2013

FDA WATCH LIST

›
4 Medications are back on the watch list of the FDA: 1. VIMPAT which could cause Neutropenia, meaning it has bone marrow suppression 2. Am...
Tuesday, February 12, 2013

›
FDA APPROVED THE GENERIC DOXIL IN REPONSE TO SHORTAGE AND ITS CONSEQUENCES ON ONCOLOGY PRACTICES ACROSS THE UNITED STATES. The Generic vers...
Wednesday, January 16, 2013

›
FDA Approval for Ixabepilone Brand name: Ixempra™       (this is old news) Approved for breast cancer Full prescribing information ...
Saturday, December 15, 2012

Ponatinib in CML

›
FDA Approvals > Medscape Medical News FDA Approves Ponatinib for Rare Leukemias Zosia Chustecka ...
›
Home
View web version

Steering Committee

Peggy Kankonde
View my complete profile
Powered by Blogger.